Printer Friendly

ONCOR, INCORPORATED ANNOUNCES EUROPEAN PARTNERSHIP WITH AMERSHAM INTERNATIONAL

 ONCOR, INCORPORATED ANNOUNCES EUROPEAN PARTNERSHIP
 WITH AMERSHAM INTERNATIONAL
 GAITHERSBURG, Md., Oct. 30 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR), announced today that it has entered into an exclusive agreement with Amersham Buchler of Braunschweig, Germany for the sale of Oncor products in Germany and via Amersham's distributors in Austria, Switzerland and certain Eastern European countries. The two companies expect to broaden their relationship to include joint development activities in the future.
 "Amersham and its subsidiaries are well established in DNA research technology and in the key markets in Europe. We are pleased to be developing the European market for our technology-leading DNA products, in close partnership with Amersham," said Oncor's President and Chief Operating Officer, George R. Evanega, Ph.D. "We are also completing arrangements for product distribution in the other key European countries, and we are optimistic that this will result in increasing our sales contribution from Europe."
 "Oncor's DNA Probe-based test systems for cancer and genetic diseases represent one of the most exciting new medical business developments that address the needs of oncologists, pathologists and cytogeneticists. Our relationship with Oncor will be strengthened by our strong technical sales forces," stated Dr. Anthony D'Eustachio, president and CEO of Amersham Buchler GmbH & Co KG.
 Under the terms of the agreement, Amersham Buchler inventories Oncor products, maintains a substantial dedicated direct sales force in the life science markets, and is committed to meeting annual sales levels.
 Oncor develops, manufactures and markets DNA probe test systems and related products for use in the diagnosis, monitoring and management of cancer and other genetic diseases.
 -0- 10/30/92
 /CONTACT: Stephen Turner or George R. Evanega, Ph.D., both of Oncor Inc., 301-963-3500, or fax 301-926-6129/
 (ONCR) CO: Oncor, Inc. ST: Maryland IN: HEA SU: JVN


LD -- NY006 -- 6953 10/30/92 08:34 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 30, 1992
Words:299
Previous Article:QUADRA LOGIC BEGINS SKIN CANCER TRIALS OF NEW DRUG IN CANADA
Next Article:FIRST UNION REPORTS TRUST INVESTMENT PERFORMANCE
Topics:


Related Articles
ONCOR COMMENCES PUBLIC OFFERING
ONCOR CONCLUDES PUBLIC OFFERING
ONCOR RECEIVES FDA MARKET APPROVAL ON SECOND GENERATION DNA-BASED TEST FOR DETECTION & MONITORING OF LEUKEMIA & LYMPHOMA
ITI CHANGES NAME TO ONCOR COMMUNICATIONS, INC., EFFECTIVE JUNE 1, 1992
ONCOR AND UNIVERSITY OF UTAH TO DEVELOP GENETIC TESTS FOR PROSTATE CANCER
ONCOR ACQUIRES AMERICAN INNOVISION
ONCOR SUBMITS FDA APPLICATION FOR CHRONIC MYELOGENOUS LEUKEMIA GENETIC TEST SYSTEM
History made with new international alliance.
RONALD DEEN APPOINTED VICE PRESIDENT, MANUFACTURING/OPERATIONS OF ONCOR, INC.
Amersham plc Announces Agreement to Sell Stake in Nycomed Holding A/S For 123 Million Pounds Sterling.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters